Subcutaneous apomorphine in the treatment of Parkinson's disease.

J P Frankel, A J Lees, P A Kempster and G M Stern

Department of Neurology, Middlesex Hospital School of Medicine, London, United Kingdom.

Apomorphine a dopamine receptor agonist was given subcutaneously to 57 levodopa treated parkinsonian patients with refractory off-period disabilities for a median period of 16 months. In 30 given intermittent suprathreshold injections the mean number of hours spent in a disabling off state fell from 6.9 to 2.9. Similar benefit was observed in 21 patients receiving continuous infusions with additional boluses on demand by mini-pump (mean reduction of hours off from 9.9 to 4.5). Twelve patients have been treated for over two years without tachyphylaxis or loss of response. The incidence of neuropsychiatric side-effects has been low (7%). Six patients failed to show a sustained worthwhile response; severe disabilities during "on" periods being the major problem. Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating "off" period disabilities refractory to oral medication and should be considered before experimental implantation procedures.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]  
• Waters, C. H., Chen, J. J. (2008). Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off''. Journal of Pharmacy Practice 21: 254-261 [Abstract]  
• Jenner, P. (2005). A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65: S3-S5 [Abstract] [Full Text]  
• LeWitt, P. A. (2004). Subcutaneously administered apomorphine: Pharmacokinetics and metabolism. Neurology 62: S8-S11 [Abstract] [Full Text]  
• Factor, S. A. (2004). Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 62: S12-S17 [Abstract] [Full Text]  
• Koller, W., Stacy, M. (2004). Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 62: S22-S26 [Abstract] [Full Text]  
• Bowron, A. (2004). Practical considerations in the use of apomorphine injectable. Neurology 62: S32-S36 [Abstract] [Full Text]  
• Varma, T R K, Fox, S H, Eldridge, P R, Littlechild, P, Byrne, P, Forster, A, Marshall, A, Cameron, H, McIver, K, Fletcher, N, Steiger, M (2003). Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J. Neurol. Neurosurg. Psychiatry 74: 170-174 [Abstract] [Full Text]  
• Clarke, C E (2002). MEDICAL MANAGEMENT OF PARKINSON'S DISEASE. J. Neurol. Neurosurg. Psychiatry 72: i22-27 [Full Text]  
• Dewey, R. B. Jr, Hutton, J. T., LeWitt, P. A., Factor, S. A. (2001). A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events. Arch Neurol 58: 1385-1392 [Abstract] [Full Text]  
• Olanow, C. W., Watts, R. L., Koller, W. C. (2001). An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment. Neurology 56: S1-S88 [Full Text]  
• Manson, A. J., Hanagasi, H., Turner, K., Patsalos, P. N., Carey, P., Ratnaraj, N., Lees, A. J. (2001). Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations. Brain 124: 331-340 [Abstract] [Full Text]  
• Münchau, A, Bhatia, K P (2000). Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 76: 602-610 [Full Text]  
• Arnulf, I., Bonnet, A.-M., Damier, P., Bejjani, B.-P., Seilhean, D., Derenne, J.-P., Agid, Y. (2000). Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis. Neurology 55: 281-288 [Abstract] [Full Text]  
• Colosimo, C., Pontieri, F. E., Evidente, V. G. H., Hardy, K. G., O'Sullivan, J. D., Lees, A. J., Hughes, A. J., Friedman, J. H., Goren, J. (1999). Yawning in Parkinson's disease. Neurology 52: 428-428 [Full Text]  
• Pietz, K., Hagell, P., Odin, P. (1998). Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry 65: 709-716 [Abstract] [Full Text]  
• Colzi, A, Turner, K, Lees, A J (1998). Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64: 573-576 [Abstract] [Full Text]  
• (1995). Drugs for Parkinson's disease reviewed. DTB 33: 49-52 [Abstract] [Full Text]  
• van Laar, T., Jansen, E. N. H., Essink, A. W. G., Neef, C. (1992). Intranasal Apomorphine in Parkinsonian On-Off Fluctuations. Arch Neurol 49: 482-484 [Abstract]  
• Henderson, B. T. H., Clough, C. G., Hughes, R. C., Hitchcock, E. R., Kenny, B. G. (1991). Implantation of Human Fetal Ventral Mesencephalon to the Right Caudate Nucleus in Advanced Parkinson's Disease. Arch Neurol 48: 822-827 [Abstract]